Routine vs. Selective Naloxone Co-Prescribing for Chronic Opioid Therapy
A patient with eleven years of impeccable adherence hears her clinic’s new universal naloxone policy as a personal accusation. The policy may be sound population-level medicine and still land badly in a specific relationship.
“Do you think I'm one of those addicts now?” B.T. asked her physician directly, and meant it. She did not react with the neutral acceptance the clinic had anticipated when he mentioned, as part of a new standing policy, that he'd be co-prescribing naloxone alongside her morphine refill going forward — as he now does for every patient on long-term opioid therapy, regardless of individual risk factors. After eleven years of what she considered a trusting relationship, it felt to her, in the moment, like an accusation rather than routine care, and she said so.
She is sixty-seven, and has come to the same pain clinic for eleven years, ever since a failed spinal fusion left her with chronic lower-back pain that morphine has kept manageable enough to still garden most mornings before the heat sets in. She retired from thirty years teaching middle-school science the year after her surgery, and describes the garden, along with her weekly calls with a former student who still checks in, as what actually got her through the hardest stretch of recovery. She has never missed a scheduled pill count, never had an aberrant urine toxicology result, and has no history of substance use disorder or psychiatric comorbidity. She lives with her husband of forty-two years, a retired postal carrier who accompanies her to most appointments and sits quietly in the corner chair he has, by now, more or less claimed as his own — he was sitting there when she asked the question, and didn't say anything at first either.
A universal offer that landed as a personal accusation
The universal policy itself should stand. The CDC's 2022 opioid prescribing guideline specifically recommends offering naloxone when a patient has known risk factors — a household member at risk, concurrent benzodiazepine use, a high daily dose — but our clinic's own broader policy is offering it to everyone, precisely because those specific risk factors don't capture everything: accidental co-ingestion, a new medication interaction, or a change in her own metabolism years from now are all real possibilities regardless of how clean her record has been. Offering naloxone to everyone, the way a smoke detector isn't a statement about your cooking, is part of what actually reduces the stigma she's reacting to right now.
I agree with the policy, but I don't think the smoke-detector framing is what actually reached her today, and that gap matters. However sound the reasoning is, if it was delivered as a brief mention folded into a routine refill conversation, without context or acknowledgment of her specific history, it's not surprising it landed as an accusation rather than routine care. The policy being right doesn't mean today's specific conversation went well.
That's a fair distinction, but I'd push back gently on treating it as purely a delivery problem — even a perfectly delivered universal offer will occasionally land hard for a patient with this specific relationship history, and that's worth naming rather than assuming a better script would have avoided it entirely.
I want to go back and have this conversation with her directly, not as a generic policy explanation but grounded in our actual eleven years together — naming specifically that this wasn't about anything she's done, walking through the real, non-behavioral risks the offer is meant to cover, and giving her room to react rather than moving straight past it. The clinic's universal policy can stay exactly as it is; what needs repair is this specific conversation with this specific patient.
Agreed: naloxone remains co-prescribed per the clinic's universal policy, and her physician returned to speak with her directly, in person, framing the offer plainly as universal equipment rather than an individual judgment.
Not agreed: whether the clinic's standard messaging script for introducing universal naloxone co-prescribing needs a broader rewrite, or whether today's rupture was more a one-off communication lapse than a systemic problem. The pain medicine specialist wants the script revised to explicitly preempt this reaction for every long-term patient; the addiction medicine specialist felt the existing framing was sound and the gap was specifically in how it was delivered today, not in the script itself.